Share This Page
Drug Price Trends for NDC 46122-0761
✉ Email this page to a colleague
Average Pharmacy Cost for 46122-0761
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GNP ASPIRIN EC 81 MG TABLET | 46122-0761-61 | 0.01481 | EACH | 2025-11-19 |
| GNP ASPIRIN EC 81 MG TABLET | 46122-0761-58 | 0.01481 | EACH | 2025-11-19 |
| GNP ASPIRIN EC 81 MG TABLET | 46122-0761-61 | 0.01492 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 46122-0761
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 46122-0761
Introduction
The drug with NDC 46122-0761 is a pharmaceutical product listed in the National Drug Code (NDC) database. Precise insights into its market dynamics and future pricing trends are essential for stakeholders, including manufacturers, healthcare providers, and investors, to optimize strategic decisions. This analysis consolidates available data, current market landscape, competitive positioning, and forecasted pricing trajectories relevant to this specific drug.
Product Overview
NDC 46122-0761 corresponds to a [specific drug name, dosage form, and strength if available, e.g., "a branded or generic molecule such as XYZ 50 mg tablets".] Released within the US healthcare system, it likely serves indications related to [list therapeutic areas, e.g., "cardiovascular health," "oncology," or "antidiabetic therapy"]. Its manufacturer is typically identified via the first segment of the NDC—here, 46122, which can be cross-referenced for proprietary information.
Efficient market penetration depends on factors such as efficacy, safety profile, patent exclusivity (if applicable), and competitive alternatives.
Market Landscape Analysis
Market Size and Demand Drivers
The demand for NDC 46122-0761 is influenced by several variables:
-
Prevalence of Indication: The drug's target condition's epidemiology directly determines potential patient pool. For example, if it addresses hypertension, the market size correlates with the hypertensive population in the US—which exceeds 100 million adults, with a significant portion (around 45%) under treatment [1].
-
Treatment Adoption Rates: Physicians’ prescribing behaviors, formulary inclusivity, and drug positioning impact utilization. Introduction to major insurance formularies and inclusion in clinical guidelines significantly boost uptake.
-
Competitive Landscape: Presence of branded alternatives, biosimilars, or generics can diminish market share and pressure pricing.
-
Regulatory and Reimbursement Factors: Medicaid/Medicare formulary coverage, prior authorization requirements, and patient copayment levels influence demand.
Pricing Benchmarks and Competitive Analysis
Pricing varies considerably across therapeutic classes, formulations, and market segments:
-
List Price and Wholesale Acquisition Cost (WAC): Currently, similar drugs in this class range from $X to $Y per unit (e.g., per tablet or vial). For instance, a comparable medication listed on Red Book reflects an average WAC of approximately $Z per dose, aligning with similar efficacy profiles.
-
Reimbursement Dynamics: Actual net prices often fall below list prices due to negotiated discounts, rebates, and patient assistance programs. These discounts typically reduce gross-to-net margins by approximately 10-30%.
-
Generic and Biosimilar Competition: The expiration of patents for similar molecules can lead to rapidly declining prices. If NDC 46122-0761 remains under patent protection, pricing stability is more assured; otherwise, aggressive price erosion may occur post-patent expiry.
Patent and Regulatory Status
The patent landscape significantly affects price projections:
-
Patent Expiry: If patent protection lapses between 1-3 years, generic entries are expected within 18-24 months, leading to substantial price reductions—often 50-80% below branded levels.
-
Regulatory Approvals: Pending or granted supplemental indications can influence market penetration and pricing strategies. Faster approval timelines typically support early premium pricing.
-
Orphan Drug Designation: If applicable, providing market exclusivity up to 7 years in the US, enabling premium pricing.
Price Projections: Short to Long Term
Short-Term Outlook (1-2 years)
-
Stability in Pricing: If the product maintains patent exclusivity and demonstrates robust market penetration, expected price stability is likely, with slight increases aligned with inflation or updated formulation costs.
-
Potential for Price Capping: Payers may pressure for discounts, especially if new competitors enter the market.
-
Rebate and Discount Trends: A moderate decline of 5-10% in net price is plausible due to increased bargaining power of payers.
Medium to Long-Term Outlook (3-5 years)
-
Patent Expiry Impact: Post-patent expiry, generic competition could drive prices down by 50-80%, depending on market size and generic uptake speed.
-
Biosimilars and Next-Generation Alternatives: Introduction of biosimilar or novel therapies can further compress pricing.
-
Market Contraction or Expansion: Adoption of value-based pricing models and expanded indications may stabilize or even increase prices if the therapy demonstrates superior outcomes.
-
Pricing in International Markets: Developed markets with high affordability standards may adopt prices comparable to the US, whereas emerging markets could see substantially lower prices due to market constraints.
Competitive and Regulatory Factors Influencing Price Trends
-
Market Exclusivity and Patent Strategies: Manufacturers leveraging patent rights and exclusivity periods will sustain premium pricing longer. Strategic patent term extensions can prolong profitability.
-
Healthcare Policy Changes: Shifts toward value-based care and stricter price controls could flatten or reduce future pricing margins.
-
Reimbursement Policies: Payer-driven formulary inclusions and tiering influence patient access and thereby impact real-world pricing strategies.
Concluding Remarks
The future pricing trajectory of NDC 46122-0761 hinges primarily on patent status, competitive landscape, and therapeutic value addition. Maintaining market exclusivity and demonstrating clinical superiority or cost-effectiveness serve as critical levers for sustaining premium prices. Conversely, upcoming patent expiries portend significant price erosion, necessitating strategic planning for long-term revenue maximization.
Key Takeaways
-
Market Size & Demand: Driven by disease prevalence and treatment adoption; substantial in prevalent conditions like hypertension but vulnerable to competitive substitutes.
-
Pricing Dynamics: Currently aligned with comparable therapeutics, influenced by list prices, rebates, and formulary negotiations; expected stability short-term, with pressure to decline post-patent expiry.
-
Competitive Risks: Patent expiry and biosimilar entry pose significant downward price risks; proactive innovation and differentiated value propositions are essential.
-
Policy & Regulatory Impact: Reimbursement reforms and healthcare policies will increasingly influence pricing strategies and profitability.
-
Strategic Recommendations: Monitor patent timelines, engage in value-based pricing models, explore global markets, and invest in differentiating clinical value.
FAQs
1. How does patent expiration affect the price of NDC 46122-0761?
Patent expiration typically leads to generic entry, causing prices to drop by 50-80%, depending on market dynamics and the number of competitors.
2. What factors influence the current pricing of this drug?
Pricing is influenced by the drug’s patent status, therapeutic efficacy, competitive landscape, reimbursement negotiations, and formulary placements.
3. Are there opportunities for price increases in the near term?
Yes. Ensuring expansion into additional indications, achieving regulatory milestones, or introducing value-added features can enable sustainable price premiums.
4. How does competitive pressure from biosimilars or generics impact overall market pricing?
Increased competition typically drives prices down, compelling manufacturers to innovate, optimize costs, and demonstrate superior value to maintain margins.
5. Can international markets impact US price projections?
Yes. High-income countries with comparable healthcare standards often adopt similar pricing, while emerging markets tend to have lower prices, influencing global strategies and revenue potential.
Sources
[1] American Heart Association. Heart Disease and Stroke Statistics—2022 Update.
[2] Red Book Pharmacy's Fundamental Reference. Various therapeutic class data.
[3] U.S. Food and Drug Administration (FDA). Patent and exclusivity data.
[4] IMS Health (IQVIA). Market Analysis for Prescription Drugs.
[5] CMS.gov. Medicare and Medicaid reimbursement policies.
Note: Exact details about NDC 46122-0761, including the specific drug name, formulation, and indications, were not available. The analysis is structured to provide a comprehensive framework applicable once detailed product data is integrated.
More… ↓
